Targeting Histamine Receptor 4 in Cholinergic Urticaria with Izuforant (LEO 152020): Results from a Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Crossover trial.

This was the first study to explore the role of H4R as a therapeutic target in urticaria. Targeting H4R with izuforant was well tolerated but did not demonstrate significant improvements in the primary endpoint and all but one prespecified exploratory endpoint in CholU vs placebo.